2012 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG Pharmaceuticals, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 26, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 8:30 am... More > 

AMAG Pharmaceuticals Announces FDA Submission of a Supplemental New Drug Application for Feraheme

Label Expansion to Include All Iron Deficiency Anemia Patients Who Cannot Take Oral Iron LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 24, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has submitted a supplemental new drug application (sND... More > 

AMAG Pharmaceuticals Announces New Data from Ferumoxytol Pivotal Phase III Broad Iron Deficiency Anemia Program Presented at ASH

New Data from an Additional Study Exploring 1 Gram Total Dose Infusion of Ferumoxytol also Presented LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 10, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that new data from two pivotal phase III clinical ... More > 

AMAG Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 7, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Frank Thomas, AMAG’s Chief Operating Officer, will present a company overview and business update at the Lazard Capital Markets 9th Annual Healthcare Confer... More > 

AMAG Pharmaceuticals, Inc. Announces that Feraheme Abstracts for the American Society of Hematology Annual Meeting are Now Available

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 6, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that four abstracts containing new data on treatment with Feraheme® (ferumoxytol) Injection for intravenous (IV) use in patients with iron deficiency anemia wit... More > 

Rienso® (Ferumoxytol) Launched in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease

Launch Triggers $15 Million Milestone Payment to AMAG LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 5, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Takeda Pharmaceutical Company Limited, AMAG’s partner in Europe, has launched ferumoxytol in ... More > 

AMAG Pharmaceuticals Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2012

Year-over-year quarterly Feraheme® sales and provider demand growth continued Reduced operating expenses by 42% from the third quarter of 2011 Updates financial guidance for 2012, raising Feraheme sales and lowerin... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on November 1, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended September 30, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 26, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended September 30, 2012 before the U.S. financial markets open on Thursday, November 1, ... More > 

Rienso® (Ferumoxytol) Receives Swiss Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 5, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy... More > 

AMAG Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 29, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will participate in two investor conferences in September. The sessions will both be conducted in a questi... More > 

AMAG Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2012

Full-year 2012 financial guidance updated based on strong first-half demand of Feraheme Product revenue and provider demand increased for second consecutive quarter Operating expenses down approximately 30% from th... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on July 26, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended June 30, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 19, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended June 30, 2012 before the U.S. financial markets open on Thursday, July 26, 2012. ... More > 

AMAG Pharmaceuticals Announces Positive Preliminary Results from its Phase III Study Evaluating Feraheme Compared to Placebo in Patients with Iron Deficiency Anemia

Feraheme® Achieves Superiority on all Primary Efficacy Endpoints Conference Call to Be Held Today at 8:00 a.m. Eastern Time LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 18, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported preliminary r... More > 

AMAG Pharmaceuticals Realigns Operating Cost Structure to Focus on Continued Feraheme Growth and Business Development Activities

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 25, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced a number of changes to its operating expenses that further align its cost structure with the company’s focus on advancing Feraheme® and expanding its product p... More > 

Rienso® (Ferumoxytol) Receives European Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease

Marketing Authorization Triggers $15 Million Milestone Payment to AMAG LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 22, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the European Commission has granted marketing authorization for ferumoxytol, ... More > 

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--May. 29, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s new chief executive officer, will present at two investor conferences in June. The presentations will include a company overview an... More > 

AMAG Pharmaceuticals Appoints William Heiden as President and Chief Executive Officer

Conference Call to be Held at 4:30 pm Eastern Time Today LEXINGTON, Mass.--(BUSINESS WIRE)--May. 9, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of William K. Heiden as president and chief executive officer, effective May 14... More > 

AMAG Pharmaceuticals Announces First Quarter 2012 Financial Results

Achieves Record Quarterly Provider Demand for Feraheme® LEXINGTON, Mass.--(BUSINESS WIRE)--May. 1, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company focused on the development and commercialization of Feraheme® (ferumoxytol) ... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on May 1, 2012 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2012

LEXINGTON, Mass., Apr 24, 2012 (BUSINESS WIRE) --AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2012 after the U.S. financial markets close on Tuesday, May 1, 2012. The announce... More > 

AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease

European Approval and Commercial Launch Trigger $30 Million in Milestones for AMAG LEXINGTON, Mass., Apr 20, 2012 (BUSINESS WIRE) --AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ... More > 

AMAG Pharmaceuticals Announces Preliminary Results from its Phase III Study Evaluating Feraheme Compared to IV Iron Sucrose in Patients with Iron Deficiency Anemia

Study Meets Primary Efficacy Endpoints LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 7, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported preliminary results from the first of two phase III studies that comprise its global registrational program for Fe... More > 

CORRECTING and REPLACING AMAG Pharmaceuticals, Inc. to Host Conference Call on March 7, 2012 at 4:30 p.m. ET to Discuss Feraheme Clinical Trial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 6, 2012-- First graph, first sentence of release should read: ...Wednesday, March 7, 2012. (sted: ...Thursday, March 7, 2012.). The corrected release reads: AMAG PHARMACEUTICALS, INC. TO HOST CONFERENCE CALL ON M... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on March 7, 2012 at 4:30 p.m. ET to Discuss Feraheme Clinical Trial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 6, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report preliminary results from the first of two phase III clinical trials of Feraheme for the treatment of iron deficiency anemia regardless of the underlying... More > 

AMAG Announces Fourth Quarter and Year End 2011 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 5, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fou... More > 

AMAG Pharmaceuticals, Inc. to Present at the 24th Annual ROTH Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 2, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate at the 24th Annual ROTH Conference on March 13 at 4:30 pm PT in Dana Point, CA. Company management will provide an over... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on March 5, 2012 at 4:30 p.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 23, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report audited consolidated financial results for the fourth quarter and year ended December 31, 2011 after the U.S. financial markets close on March 5... More > 

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 13, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will provide a brief overview of the company followed by a question and answer period with investors at the following investor conferences duri... More > 

AMAG Pharmaceuticals Announces the Appointment of Two Independent Directors to its Board

~Evaluation of Strategic Alternatives Ongoing~ LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 7, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of Rajiv De Silva and Gino Santini to its board of directors, effective immediately. Mr. ... More > 

AMAG Pharmaceuticals Announces Completion of Enrollment in its Phase III Program Evaluating Feraheme for a Broader Iron Deficiency Anemia Indication

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 30, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the completion of patient enrollment in the second of the company’s two phase III studies that comprise its global registrational program for Feraheme® (ferumo... More > 

AMAG Pharmaceuticals Provides Business Update

Announces Preliminary Fourth Quarter 2011 Financial Results and Reiterates 2012 Financial Outlook LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 9, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced a business update, including preliminary fourth quarter 2011 financial results and its outlo... More > 

AMAG Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 4, 2012-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Frank E. Thomas, chief operating officer and interim CEO, will provide an update on the Company followed by a breakout session at the 30th Annual J.P. Morgan Healthcare Conference on... More >